The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Initial results from a first-in-human phase 1 study of SNS-101 (pH-selective anti-VISTA antibody) alone or in combination with cemiplimab in patients with advanced solid tumors.
 
Shiraj Sen
Employment - Roche/Genentech
Stock and Other Ownership Interests - Roche/Genentech
Consulting or Advisory Role - Revolution Medicines (Inst); Roche/Genentech (Inst)
Research Funding - ABM (Inst); Arcus Biosciences (Inst); BeiGene (Inst); Centessa Pharmaceuticals (Inst); Cullinan Oncology (Inst); Dicerna (Inst); Georgiamune (Inst); Gilead Sciences (Inst); IconOVir Bio (Inst); IDEAYA Biosciences (Inst); ImmunoGenesis (Inst); OncoResponse (Inst); Parthenon Therapeutics (Inst); Pyxis (Inst); Pyxis (Inst); Revolution Medicines (Inst); Sensei Biotherapeutics (Inst); Tallac Therapeutics (Inst); Vividion Therapeutics (Inst); Zentalis (Inst)
 
Justin A Call
No Relationships to Disclose
 
Kyriakos P. Papadopoulos
Consulting or Advisory Role - Basilea; Bicycle Therapeutics; Turning Point Therapeutics
Research Funding - 3D Medicines (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); Anheart Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Biontech (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); F-star (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Kezar Life Sciences (Inst); Lilly (Inst); Linnaeus Therapeutics (Inst); MabSpace Biosciences (Inst); Merck (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Monte Rosa Therapeutics (Inst); Pfizer (Inst); PharmaMar (Inst); Regeneron (Inst); Revolution Medicines (Inst); Sensei Biotherapeutics (Inst); Storm Therapeutics (Inst); Syros Pharmaceuticals (Inst); Tempest Therapeutics (Inst); Treadwell Therapeutics (Inst)
 
F. Donelson Smith
Employment - Sensei Biotherapeutics
Stock and Other Ownership Interests - Sensei Biotherapeutics
Research Funding - Sensei Biotherapeutics
Travel, Accommodations, Expenses - Sensei Biotherapeutics
 
Janine McDermott
Employment - Sensei Biotherapeutics
Stock and Other Ownership Interests - Back Bay Scientific; Ikena Oncology; Sensei Biotherapeutics
Research Funding - Sensei Biotherapeutics
Travel, Accommodations, Expenses - Sensei Biotherapeutics; Sotio
 
Edward van der Horst
Employment - Sensei Biotherapeutics
Leadership - Sensei Biotherapeutics
Stock and Other Ownership Interests - Sensei Biotherapeutics
Research Funding - Sensei Biotherapeutics
Patents, Royalties, Other Intellectual Property - Filed patent applications on our internal VISTA program. (Inst)
Travel, Accommodations, Expenses - Sensei Biotherapeutics
 
Aaron Weitzman
Employment - Sensei Biotherapeutics
Leadership - Sensei Biotherapeutics; Tango Therapeutics
Stock and Other Ownership Interests - Quadriga; Sensei Biotherapeutics; Tango Therapeutics
Consulting or Advisory Role - Abbvie; Alpha-9 Theranostics; Biosion; Halda Therapeutics; Sensei Biotherapeutics (I); Tango Therapeutics
Travel, Accommodations, Expenses - Sensei Biotherapeutics; Tango Therapeutics